Uncategorized
Shire submits new drug application for lifitegrast
Shire Pharmaceuticals has submitted a new drug application to the FDA for lifitegrast for the treatment of dry eye disease in adults.“It is a very exciting time for the organization,” Robert Dempsey, leader of Shire’s Ophthalmics Business Unit, told Healio.com/OSN at Hawaiian Eye 2015. “As we are in the process of filing a new drug application for lifitegrast for the treatment of dry eye disease, we are, in support of this file, building out the commercial, research and development, and medical affairs infrastructure.”